Clusterin

ALZPEDIA Clusterin is a highly conserved glycoprotein that functions primarily as an extracellular chaperone. Multiple large genome-wide association studies (GWAS) have uncovered clusterin variants that strongly associate with late-onset Alzheimer’s disease, earni

APOE

ALZPEDIA Apolipoprotein E is a secreted apolipoprotein involved in lipid metabolism. It complexes with lipids to form lipoprotein particles that transport cholesterol and triglycerides via the bloodstream and facilitate the transfer of cholesterol and phospholipid

Jean Georges on AD Trial Simulation Tool Receives Regulators’ Blessings

COMMENT The patient and carer community in Europe was disappointed by the failures of recent clinical trials in the field of Alzheimer’s disease. Alzheimer Europe therefore welcomes research into the development of simulation models for clinical trials that hopef

PAPER Rajput A, Rajput AH, Rajput ML, Encarnacion M, Bernales CQ, Ross JP, Farrer MJ, Vilariño-Güell C

Identification of FUS p.R377W in essential tremor.

Eur J Neurol. 2013 Jul 3; PubMed: 23834483

PAPER Nishimoto Y, Nakagawa S, Hirose T, Okano HJ, Takao M, Shibata S, Suyama S, Kuwako K, Imai T, Murayama S, Suzuki N, Okano H

The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral sclerosis.

Mol Brain. 2013;6:31. PubMed: 23835137

PAPER Lilo E, Wald-Altman S, Solmesky LJ, Ben Yaakov K, Gershoni-Emek N, Bulvik S, Kassis I, Karussis D, Perlson E, Weil M

Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1G93A mouse model.

Hum Mol Genet. 2013 Jul 23; PubMed: 23836781

AD Trial Simulation Tool Receives Regulators’ Blessings

RESEARCH NEWS 2013-07-11 Research News Regulatory agencies in the U.S. and Europe have endorsed a quantitative simulation tool that allows researchers to model clinical trials in mild to moderate Alzheimer’s disease. The freely available tool will allow researchers to optimize th

PAPER

Medicine: Stem cells guide Alzheimer's drugs.

Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2013 Mar;29(2):116-8, 127. PubMed: 23446384

PAPER Li YL, Hou Y, Niu C, Yu LX, Cheng YY, Hong Y

[The clinical studies of hyperhomocysteinemia and Alzheimer's disease].

Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2013 Mar;29(2):116-8, 127. PubMed: 23833960

PAPER Chakrabarti S, Sinha M, Thakurta IG, Banerjee P, Chattopadhyay M

Oxidative Stress and Amyloid Beta Toxicity in Alzheimer's Disease: Intervention in a Complex Relationship by Antioxidants.

Curr Med Chem. 2013 Jun 25; PubMed: 23834172

PAPER Weinstein JD, Gonzalez ER, Egleton RD, Hunt DA

A paradigm shift for evaluating pharmacotherapy for Alzheimer's disease: the 10-patient screening protocol.

Consult Pharm. 2013 Jul;28(7):443-54. PubMed: 23835462

PAPER Chmielnicki E

Alzheimer's disease: Micrological modulation.

Nat Med. 2013 Jul;19(7):826. PubMed: 23836226

PAPER Tsvetkova D, Obreshkova D, Zheleva-Dimitrova D, Saso L

Antioxidant Activity of Galantamine and some of its Derivatives.

Curr Med Chem. 2013 Jun 25; PubMed: 23834167

PAPER Andrieux K, Couvreur P

Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: the example of Alzheimer's disease.

Ann Pharm Fr. 2013 Jul;71(4):225-33. PubMed: 23835020

PAPER Dartigues JF, Foubert-Samier A, Helmer C

[Relationship between educational level and dementia: Social factor and age-related chronic disease].

Rev Epidemiol Sante Publique. 2013 Aug;61 Suppl 3:S195-8. PubMed: 23835147